Studier på: kronisk rhinosinuitis med næsepolypper (CRSwNP)

Registreringsstudie på CRSwNP og Dupixent

SINUS24/52
Registreringsstudie fra LIBERTY

SINUS24/52: Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trial.

Bachert C et al. Lancet, 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.

Læs studiet her

Subpublikationer af SINUS24/52 - CRSwNP

NPS SCORE

Dupilumab improved objective and patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and complete nasal obstruction
Martin Wagenmann, Claus Bachert, Claire Hopkins, Mark Corbett, Jérôme Msihid, Scott Nash, Yamo Deniz, Paul J. Rowe, Harry Sacks, Juby A. Jacob-Nara

Læs studiet her

NSAID-ERD

Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.

Mullol J et al. Allergy. 2021;00:1–14. DOI: 10.1111/all.15067

Læs studiet her

ALLERGI VS IKKE ALLERGI

Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis

Peters AT, Wagenmann M, Bernstein JA, Khan AH, Nash S, Jacob-Nara JA, Siddiqui S, Rowe PJ, Deniz Y. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis. Allergy Asthma Proc. 2023 Jul 1;44(4):265-274. doi:10.2500/aap.2023.44.230015.

Læs studiet her

LUGTESANS

The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP

Lee et al. Rhinology. 2023 Jul 15. doi: 10.4193/Rhin22.220. Epub ahead of print. PMID: 37453138.

Læs studiet her

ASTMA OG SCS

Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma

Mark Gurnell, Amr Radwan, Claus Bachert, Njira Lugogo, Seong H Cho, Scott Nash, Haixin Zhang, Asif H Khan, Juby A Jacob-Nara, Paul J Rowe, Yamo Deniz

Journal of Asthma and Allergy, 16 January 2024 Volume 2024:17 Pages 1—8 https://doi.org/10.2147/JAA.S420140

Læs studiet her

TYPE 2 INFLAMMATION

Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52

Claus Bachert MD, PhD, Asif H. Khan MBBS, PhD, MPH, Stella E. Lee MD, Claire Hopkins DM, Anju T. Peters MD, Wytske Fokkens MD, PhD, Amy Praestgaard MSc, Amr Radwan MB, BChir, Scott Nash MD, Juby A. Jacob-Nara MD, Yamo Deniz MD, Paul J. Rowe MD

Int Forum Allergy Rhinol. 2023;1–11. DOI: 10.1002/alr.23249

Læs studiet her

Andre studier på CRSwNP og Dupixent

RWE - DUPIREAL - ITALIEN

Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL)

Eugenio De Corso et al. 2023 https://doi.org/10.1111/all.15772

Læs studiet her

META-ANALYSE

Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis

Paul Oykhman, MD, MSc, et al. https://doi.org/10.1016/j.jaci.2021.09.009

Læs studiet her

Pligttekst Dupixent^® (dupilumab)